Home
About Us
leadership
board of directors
investors
Pipeline
Development Status
PS CB1 Program
News & Information
Contact Us
JD5037 - API and Formulation
Straightforward 5-step synthesis (5.2 kg GMP API synthesized) to single active isomer (97.4% active diastereomer).
Sufficient GMP material is on hand to complete Phase 1a /1b trials; 48 month stability data on API.
Adequate hard gelatin capsules have been manufactured for early clinical studies in two dosage levels.
US Patent 8,680,131 (3/25/14) covers individual isomers.
Milestones and Plans
The IND application on JD5037 was filed 11/17 and was allowed 12/17.
JD5037 and Jenrin’s library of compounds targeting the CB1 receptor were licensed to Corbus Pharmaceuticals 9/20/18
Copyright 2017 Jenrin Discovery - All Rights Reserved